These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8969318)

  • 1. Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials?
    O'Brien B
    Med Care; 1996 Dec; 34(12 Suppl):DS99-108. PubMed ID: 8969318
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic assessment within the clinical development program.
    Schulman KA; Llana T; Yabroff KR
    Med Care; 1996 Dec; 34(12 Suppl):DS89-95. PubMed ID: 8969317
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug therapy: safety, effectiveness, and economics.
    Brandys J
    Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.
    Maetzel A; Tugwell P; Boers M; Guillemin F; Coyle D; Drummond M; Wong JB; Gabriel SE;
    J Rheumatol; 2003 Apr; 30(4):891-6. PubMed ID: 12672224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluations alongside equivalence and noninferiority trials.
    Gandjour A
    Value Health; 2009 Jun; 12(4):628; author reply 629. PubMed ID: 19900261
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacoeconomic component of a clinical trial conducted in Latin America. Conceptual and empirical considerations.
    Reinharz D; Saldaña VR; Follador W; Asche C
    Int J Technol Assess Health Care; 2001; 17(4):571-8. PubMed ID: 11758300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of the comparator in economic evaluations: working on the efficiency frontier.
    Neyt M; Van Brabandt H
    Pharmacoeconomics; 2011 Nov; 29(11):913-6. PubMed ID: 21988290
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
    Bennett CL; Oddone E; Matchar D
    Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of health economic information by reimbursement authorities.
    Drummond MF
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii60-3. PubMed ID: 14585919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Conducting a cost-effectiveness trial in oncology: justification and method].
    Lejeune C; Binquet C; Bonnetain F
    Bull Cancer; 2009 May; 96(5):603-7. PubMed ID: 19435689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomics: integrating economic evaluation into clinical trials.
    Haycox A; Drummond M; Walley T
    Br J Clin Pharmacol; 1997 Jun; 43(6):559-62. PubMed ID: 9205814
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining types of economic evaluation.
    Ngorsuraches S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S21-7. PubMed ID: 19255985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis.
    Evans WK; Coyle D; Gafni A; Walker H;
    Chronic Dis Can; 2003; 24(4):102-7. PubMed ID: 14733759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does cost-effectiveness play a role in clinical trials?
    Steele T; Pawaskar M; Balkrishnan R; Fleischer A; Feldman SR
    Dermatol Ther; 2007; 20(2):110-9. PubMed ID: 17537139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical industry research and cost savings in community-acquired pneumonia.
    Kessler LA; Waterer GW; Barca R; Wunderink RG
    Am J Manag Care; 2002 Sep; 8(9):798-800. PubMed ID: 12234020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managed care guidelines for the economic evaluation of pharmaceuticals.
    Langley PC; Martin RE
    Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.